Portal vein tumor thrombosis in hepatocellular carcinoma patients:Is it the end?
10.1016/j.livres.2024.09.002
- Author:
Abdelhamed WALAA
1
;
Shousha HEND
;
El-Kassas MOHAMED
Author Information
1. Endemic Medicine Department
- Keywords:
Hepatocellular carcinoma(HCC);
Portal vein tumor thrombosis(PVTT);
Staging;
Systemic therapies;
Locoregional treatment;
Immunotherapy
- From:
Liver Research
2024;8(3):141-151
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is the sixth most prevalent form of cancer globally and the third leading cause of cancer-related mortality.The incidence of portal vein tumor thrombosis(PVTT)in HCC patients is 21％at one year and 46％at three years.The presence of PVTT has consistently been associated with a poor prognosis for HCC patients over the past decades.Notably,HCC prognosis is influenced not only by the presence of PVTT but also by the degree or extent of PVTT.Currently,there is a lack of global consensus or established protocols regarding the optimal management of HCC with associated PVTT.The Barcelona Clinic for Liver Cancer classifies HCC patients with PVTT as stage C,indicating an advanced stage,and limiting treatment recommendations for these patients to systemic therapy.In recent years,there has been an increase in the availability of therapeutic options for HCC patients with PVTT.Treat-ment modalities include systemic therapy,transarterial chemoembolization,surgical resection,stereo-tactic body radiotherapy,transarterial radioembolization,and liver transplantation.An ideal therapy for each patient necessitates a multidisciplinary approach.This review article presents the latest updates in managing HCC patients with PVTT.
